1541 fundamentals
An in-depth look to IMMUNEONCO BIOPHARMACEUTICALS (SHAN operating, investing, and financing activities
1541 free cash flow for H2 24 is -8.79 M HKD. For 2024, 1541 free cash flow was -145.94 M HKD and operating cash flow was -134.66 M HKD.
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: HKD
TTM